Filing Flows › Amneal Pharmaceuticals (AMRX) › Q2 2026
Amneal Pharmaceuticals (AMRX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Amneal Pharmaceuticals (AMRX) reported revenue of $796M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +10% from the quarter before. Operating margin was 16.3%, net earnings $57.7M (7.2% of revenue).
Amneal Pharmaceuticals, Q2 2026: revenue $796M (+10% year over year), operating margin 16.3%, net earnings $57.7M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $796M | +10% | +10% |
| Gross profit | $335M | +4% | +17% |
| Operating profit | $130M | -8% | +17% |
| Net earnings | $57.7M | -7% | +157% |
| Operating cash flow | −$21.2M | — | -125% |
What changed
Revenue was $796.2M in Q2 2026, up 10% year over year and up 10% from the previous quarter. Affordable Medicines was the largest line at 62% of revenue. Affordable Medicines added $56.5M year over year (up 13%), 79% of the total change. AvKARE declined 4%.
Gross margin was 42.0%, up 2.5 points from Q2 2025. Operating profit was $129.8M, a 16.3% margin (up 0.9 points year over year). Of the extra revenue versus Q2 2025, 26% reached operating profit, above the 15% margin then. Operating expenses grew 17% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+541%). Net earnings were $57.7M, up 157% year over year. The effective tax rate was 1.9%.
Operating cash flow was −$21.2M. Non-cash charges added back $10.4M of share-based compensation. Working capital and other items used $101.2M. Capital expenditures of $30.7M exceeded it, leaving free cash flow of −$51.9M.
Questions
What was Amneal Pharmaceuticals' revenue in the second quarter 2026?
Amneal Pharmaceuticals (AMRX) reported revenue of $796M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +10% from the quarter before.
Was Amneal Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $130M (16.3% of revenue) and net earnings $57.7M.